This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fahmi, H.
Right arrow Articles by Joab, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fahmi, H.
Right arrow Articles by Joab, I.

 Previous Article  |  Next Article 

Journal of Virology, July 2000, p. 5810-5818, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Transforming Growth Factor Beta 1 Stimulates Expression of the Epstein-Barr Virus BZLF1 Immediate-Early Gene Product ZEBRA by an Indirect Mechanism Which Requires the MAPK Kinase Pathway

Hassan Fahmi,1,2 Chantal Cochet,1 Zakariae Hmama,2 Paule Opolon,3 and Irene Joab1,*

Laboratory of Immunology, Faculty of Science, Université Sidi Mohamed Ben Abdellah, Fès, Morocco,2 and Laboratoire de Pharmacologie Expérimentale et Clinique, INSERM EPI 99-32, Institut de Génétique Moléculaire, 75010 Paris,1 and CNRS UMR 1582, Institut Gustave Roussy, 94800 Villejuif,3 France

Received 9 December 1999/Accepted 4 April 2000

Disruption of Epstein-Barr virus (EBV) latency is mediated by ZEBRA, the protein product of the immediate-early EBV gene, BZLF1. In vitro, phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC), induces reactivation of EBV. However, the physiological stimuli responsible for the disruption of viral latency are not well characterized. Transforming growth factor beta 1 (TGF-beta 1) has also been shown to trigger the reactivation of EBV in Burkitt lymphoma cell lines; however, the effect of TGF-beta 1 on ZEBRA expression has not been reported. To further understand this phenomenon, we have investigated the effect of TGF-beta 1 on ZEBRA expression. Our results indicate that the treatment of different EBV-positive Burkitt's lymphoma cell lines with TGF-beta 1 induces a time-dependent activation of BZLF1 transcription with a corresponding increase in the production of the protein ZEBRA. TGF-beta 1 has been shown to exert its effects through a wide range of intracellular routes; in the present study, we have explored these pathways. Transient expression of Smad proteins on their own had no effect on ZEBRA expression. A specific inhibitor of p38 mitogen-activated protein kinase (MAPK), SB203580, did not affect TGF-beta 1-induced ZEBRA expression, whereas treatment with the MAPK/ERK kinase inhibitors, PD98059 and U0126, dramatically decreased this induction. This suggests that TGF-beta 1 effect on BZLF1 expression requires the MAPK pathway. However, in Raji and B95-8 cells additional routes can be used, as (i) the inhibition of ZEBRA induction by PD98059 or U0126 was incomplete, whereas these inhibitors completely abolished PMA-induced ZEBRA expression, (ii) TGF-beta 1 induction of ZEBRA expression occurs in PKC-depleted cells, (iii) in Raji and in B95-8 cells, the effect of TGF-beta 1 and PMA are additive. Transient transfection of the EBV-negative B-cell line DG75 with a BZLF1 promoter-fusion construct (Zp-CAT) showed that under conditions where the BZLF1 promoter is activated by PMA treatment, TGF-beta 1 had no significant effect on the expression of the chloramphenicol acetyltransferase gene. Furthermore, TGF-beta 1 induction of BZLF1 transcripts is dependent on de novo protein synthesis, which suggests that TGF-beta 1 induces BZLF1 expression by an indirect mechanism.

* Corresponding author. Mailing address: Laboratoire de Pharmacologie Expérimentale et Clinique, INSERM EPI 99-32, Institut de Génétique Moléculaire, 27 rue Juliette Dodu, 75010 Paris, France. Phone: 33 (1) 42 49 92 68. Fax: 33 (1) 42 49 48 38. E-mail: i.joab{at}chu-stlouis.fr.

Journal of Virology, July 2000, p. 5810-5818, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lee, Y.-H., Chiu, Y.-F., Wang, W.-H., Chang, L.-K., Liu, S.-T. (2008). Activation of the ERK signal transduction pathway by Epstein-Barr virus immediate-early protein Rta. J. Gen. Virol. 89: 2437-2446 [Abstract] [Full Text]  
  • Malizia, A. P., Keating, D. T., Smith, S. M., Walls, D., Doran, P. P., Egan, J. J. (2008). Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGF{beta}1 expression. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L451-L460 [Abstract] [Full Text]  
  • Chang, Y., Lee, H.-H., Chen, Y.-T., Lu, J., Wu, S.-Y., Chen, C.-W., Takada, K., Tsai, C.-H. (2006). Induction of the early growth response 1 gene by epstein-barr virus lytic transactivator zta.. J. Virol. 80: 7748-7755 [Abstract] [Full Text]  
  • Huang, J., Liao, G., Chen, H., Wu, F. Y., Hutt-Fletcher, L., Hayward, G. S., Hayward, S. D. (2006). Contribution of C/EBP Proteins to Epstein-Barr Virus Lytic Gene Expression and Replication in Epithelial Cells. J. Virol. 80: 1098-1109 [Abstract] [Full Text]  
  • Dierksheide, J. E., Baiocchi, R. A., Ferketich, A. K., Roychowdhury, S., Pelletier, R. P., Eisenbeis, C. F., Caligiuri, M. A., VanBuskirk, A. M. (2005). IFN-{gamma} gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood 105: 1558-1565 [Abstract] [Full Text]  
  • Laichalk, L. L., Thorley-Lawson, D. A. (2005). Terminal Differentiation into Plasma Cells Initiates the Replicative Cycle of Epstein-Barr Virus In Vivo. J. Virol. 79: 1296-1307 [Abstract] [Full Text]  
  • Feng, W.-h., Cohen, J. I., Fischer, S., Li, L., Sneller, M., Goldbach-Mansky, R., Raab-Traub, N., Delecluse, H.-J., Kenney, S. C. (2004). Reactivation of Latent Epstein-Barr Virus by Methotrexate: A Potential Contributor to Methotrexate-Associated Lymphomas. JNCI J Natl Cancer Inst 96: 1691-1702 [Abstract] [Full Text]  
  • Feng, W.-h., Hong, G., Delecluse, H.-J., Kenney, S. C. (2004). Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas. J. Virol. 78: 1893-1902 [Abstract] [Full Text]  
  • Touitou, R., Arbach, H., Cochet, C., Feuillard, J., Martin, A., Raphael, M., Joab, I. (2003). Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines. J. Gen. Virol. 84: 949-957 [Abstract] [Full Text]  
  • Gutierrez, M. I., Ibrahim, M. M., Dale, J. K., Greiner, T. C., Straus, S. E., Bhatia, K. (2002). Discrete Alterations in the BZLF1 Promoter in Tumor and Non-Tumor-Associated Epstein-Barr Virus. JNCI J Natl Cancer Inst 94: 1757-1763 [Abstract] [Full Text]  
  • Binne, U. K., Amon, W., Farrell, P. J. (2002). Promoter Sequences Required for Reactivation of Epstein-Barr Virus from Latency. J. Virol. 76: 10282-10289 [Abstract] [Full Text]  
  • Liang, C.-L., Chen, J.-L., Hsu, Y.-P. P., Ou, J. T., Chang, Y.-S. (2002). Epstein-Barr Virus BZLF1 Gene Is Activated by Transforming Growth Factor-beta through Cooperativity of Smads and c-Jun/c-Fos Proteins. J. Biol. Chem. 277: 23345-23357 [Abstract] [Full Text]  
  • Gradoville, L., Kwa, D., El-Guindy, A., Miller, G. (2002). Protein Kinase C-Independent Activation of the Epstein-Barr Virus Lytic Cycle. J. Virol. 76: 5612-5626 [Abstract] [Full Text]  
  • Feng, W.-h., Israel, B., Raab-Traub, N., Busson, P., Kenney, S. C. (2002). Chemotherapy Induces Lytic EBV Replication and Confers Ganciclovir Susceptibility to EBV-positive Epithelial Cell Tumors. Cancer Res. 62: 1920-1926 [Abstract] [Full Text]  
  • Inman, G. J., Binné, U. K., Parker, G. A., Farrell, P. J., Allday, M. J. (2001). Activators of the Epstein-Barr Virus Lytic Program Concomitantly Induce Apoptosis, but Lytic Gene Expression Protects from Cell Death. J. Virol. 75: 2400-2410 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»